CMBE | JCSMR | ANU | Search ANU
The Australian National University
The John Curtin School of Medical Research
ANU College of Medicine, Biology & Environment

Muscle Research Group

Angela Dulhunty
Professor and Group Leader

T: +61 2 6125 4491
F: +61 2 6125 4761
E: Angela.Dulhunty@anu.edu.au

Mail Address:
Structural Biology Program
The John Curtin School of Medical Research
GPO Box 334
Canberra ACT 2601 Australia

Professor Angela Dulhunty


We welcome
Australian, New Zealand and International students who would like to join in these studies, either as a part of laboratory experience for undergraduate courses, for Honours projects or for Masters or PhD studies. Interested students should contact angela.dulhunty@anu.edu.au or go to http://jcsmr.anu.edu.au/students/index.php for more general information.


 

The Muscle Research Group studies molecular interactions between two Ca2+ ion channels that underlie Ca2+ signalling in muscle. The channels are the dihydropyridine receptor (DHPR) Ca2+ channel in the surface membrane and the ryanodine receptor (RyR) Ca2+ release channel in the sarcoplasmic reticulum (SR) Ca2+ store. These proteins are essential for movement. Excitation-contraction (EC) coupling is broadly defined as the signal transduction process that links an action potential to contraction, but more narrowly encapsulates the processes that intervene between depolarization of the surface membrane and Ca2+ release from the SR. EC coupling in the heart depends on RyR activation by Ca2+ ions that enter through the DHPR ion channel. In marked contrast EC coupling in skeletal muscle does not depend on external Ca2+. Instead, a depolarisation-dependent signal is transmitted from the DHPR to the RyR by conformational coupling between the two proteins. Proper Ca2+ signalling depends (a) the activity of the RyR during EC coupling and (b) on the amount of Ca2+ available for release within the Ca2+ store. The factors that set RyR channel activity and the Ca2+ load within the store are the focus of our investigations.
Although many of our questions are very basic, the research is increasingly directed to understanding disease-related mutations in the proteins that are linked to debilitating skeletal myopathies and to fatal cardiomyopathies. The long term goal in this regard is the rational design of drugs that might help alleviate the symptoms of these disorders.